Image source: Thermo Fisher Scientific

Development of a highly sensitive analytical workflow

Collaboration for infectious disease diagnosis and patient monitoring

Thermo Fisher Scientific and NanoPin Technologies, Inc. have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.

Through the detection of disease-related antigens directly from patient blood samples, NanoPin's unique diagnostic platform using Thermo Fisher's advanced LC-MS technology will lead to the development of sensitive clinical assays for infectious disease. This will enable healthcare providers to reduce time to results, determine infection stage and monitor patient response to prescribed treatment. The quantified information gleaned from the combined technology will support clinical decision-making and the provision of personalized patient care unique to their disease state.

The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments

Thomas Tombler

"Time is critical when it comes to the diagnosis and treatment of patients suffering from infectious disease, and current methods do not facilitate prompt diagnosis and rapid evaluation of treatment response," said Bradley Hart, senior director, clinical research, chromatography and mass spectrometry, Thermo Fisher Scientific.

Dr. Thomas Tombler, chief executive officer, NanoPin Technologies, said, "The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments. Through our agreement with Thermo Fisher, our unique diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated and controlled by solving the unmet needs of healthcare providers managing patient care throughout the world."


Source: Thermo Fisher Scientific

14.02.2020

Read all latest stories

Related articles

Photo

Liquid chromatography/mass spectrometry

LC-MS: Calling for easy-to-use platforms

Liquid chromatography/mass spectrometry (LC-MS) is an established powerful tool in routine clinical use and clinical research. However, to further capitalise on its benefits, instrument and…

Photo

Testing technology

Vitamin D testing: LC-MS outperforms immunoassays

In recent years, clinicians have increasingly focused on vitamin D deficiency. Studies show that previous reference values – particularly for Vitamin D3 – were most probably set too high. Liquid…

Photo

LC-MS/MS

Wanted: automated clinical analyser with broad, expandable testing menu

Combining the physical separation power of liquid chromatography with the mass analysis capability of mass spectrometry – i.e. liquid chromatography tandem mass spectrometry (LC-MS/MS) – enables…

Related products

Thermo Fisher Scientific – Cascadion SM

Mass Spectrometry

Thermo Fisher Scientific – Cascadion SM

Thermo Fisher Scientific
Thermo Fisher Scientific – TSQ Altis MD

Mass Spectrometry

Thermo Fisher Scientific – TSQ Altis MD

Thermo Fisher Scientific
Thermo Fisher Scientific – TSQ Quantis MD

Mass Spectrometry

Thermo Fisher Scientific – TSQ Quantis MD

Thermo Fisher Scientific
Thermo Fisher Scientific – Vanquish MD HPLC

Electrophoresis / Chromatography

Thermo Fisher Scientific – Vanquish MD HPLC

Thermo Fisher Scientific
Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
Beckman Coulter – DxONE Command Central Workstation

LIS, Middleware, POCT

Beckman Coulter – DxONE Command Central Workstation

Beckman Coulter, Inc.